164 related articles for article (PubMed ID: 23300780)
1. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated.
Krakstad C; Birkeland E; Seidel D; Kusonmano K; Petersen K; Mjøs S; Hoivik EA; Wik E; Halle MK; Øyan AM; Kalland KH; Werner HM; Trovik J; Salvesen H
PLoS One; 2012; 7(12):e52795. PubMed ID: 23300780
[TBL] [Abstract][Full Text] [Related]
2. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
[TBL] [Abstract][Full Text] [Related]
3. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.
Rudd ML; Price JC; Fogoros S; Godwin AK; Sgroi DC; Merino MJ; Bell DW
Clin Cancer Res; 2011 Mar; 17(6):1331-40. PubMed ID: 21266528
[TBL] [Abstract][Full Text] [Related]
4. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
5. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
[TBL] [Abstract][Full Text] [Related]
6. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
7. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract][Full Text] [Related]
8. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB
Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
[TBL] [Abstract][Full Text] [Related]
11. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
12. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study.
Mayo-de-Las-Casas C; Velasco A; Sanchez D; Martínez-Bueno A; Garzón-Ibáñez M; Gatius S; Ruiz-Miró M; Gonzalez-Tallada X; Llordella I; Tresserra F; Rodríguez S; Aldeguer E; Roman-Canal B; Bertran-Alamillo J; García-Peláez B; Rosell R; Molina-Vila MA; Matias-Guiu X
Int J Cancer; 2020 Jul; 147(1):277-284. PubMed ID: 31953839
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
15. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
[TBL] [Abstract][Full Text] [Related]
16. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
[TBL] [Abstract][Full Text] [Related]
17. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
[TBL] [Abstract][Full Text] [Related]
19. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
Bozzao C; Varvara D; Piglionica M; Bagnulo R; Forte G; Patruno M; Russo S; Piscitelli D; Stella A; Resta N
Int J Biol Markers; 2012 Dec; 27(4):e366-74. PubMed ID: 23125007
[TBL] [Abstract][Full Text] [Related]
20. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.
Bruckman KC; Schönleben F; Qiu W; Woo VL; Su GH
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov; 110(5):632-7. PubMed ID: 20813562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
